Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Relapsed or Resistant Multiple Myeloma
NCT00253578Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoints: Overall Response Rate at 3 years, Incidence of qualitative and quantitative toxicities at 3 years and 2 more. Started Mar 2006; status: completed.
02
Drugs
sorafenib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00253578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00253578.